Has Arashk Motiei, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,335 in general payments to Arashk Motiei, MD across 18 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Arashk Motiei, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Arashk Motiei, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Arashk Motiei, MD

Cardiovascular Disease · Rochester, MNNPI 1225000748

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $449 and has fallen 83.6% since, to $74 in 2025.

$1,335in general payments, 2019–2025

Across 18 payments — averaging $74.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Inari Medical, Inc.$235
Biotronik Inc.$234
Medtronic$214
Penumbra, Inc.$160
Abiomed$119
Terumo Medical Corporation$115
plus $257 from 6 others

$45,500in research payments, 2019–2025

Across 2 payments — averaging $22,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Inari Medical, Inc.$27K
Boston Scientific$19K

What the payments were for

Food & beverage$1,335100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Inari Medical, Inc.	2	$235
Biotronik Inc.	2	$234
Medtronic	3	$214
Penumbra, Inc.	2	$160
Abiomed	1	$119
Terumo Medical Corporation	1	$115
Angiodynamics, Inc.	1	$103
Stryker	1	$74
Bard Peripheral Vascular, Inc.	2	$34
Shockwave Medical, Inc	1	$19
Silk Road Medical, Inc.	1	$17
Amgen	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,335 in reported general payments places this provider in the 55th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota →

Medicare billing

Part B allowed, 2024

$76,794

Medicare patients

216

Services billed

634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ezetimibe	18	$1,501
Rosuvastatin Calcium	84	$963
ClopidogrelClopidogrel Bisulfate	17	$235
Cilostazol	15	$231
Atorvastatin Calcium	24	$183
Metoprolol Succinate	15	$91
Amlodipine Besylate	18	$33

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Rochester

Srijoy MahapatraRochester$1.2M
Charanjit RihalRochester$478K
Amir LermanRochester$465K
Martha GroganRochester$330K
Virend SomersRochester$262K
Francisco Lopez-JimenezRochester$167K
Ammar KilluRochester$139K
Allan JaffeRochester$111K
Robert McBaneRochester$110K
Michael McGoonRochester$106K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →